Hepatitis D (HDV, Requires HBV Co-Infection)
Overview
Plain-Language Overview
Hepatitis D (HDV) is a viral infection that affects the liver, the organ responsible for filtering toxins and aiding digestion. This infection only occurs in people who already have Hepatitis B virus (HBV) because HDV needs HBV to replicate. It can cause inflammation and damage to the liver, leading to symptoms like fatigue, jaundice (yellowing of the skin and eyes), and abdominal pain. The infection can worsen liver disease more rapidly than Hepatitis B alone, increasing the risk of serious problems like cirrhosis or liver failure. Because it depends on HBV, preventing or managing Hepatitis B is important to control HDV infection.
Clinical Definition
Hepatitis D virus (HDV) infection is a defective RNA virus that requires the presence of Hepatitis B virus (HBV) for its replication and assembly, as it uses HBV surface antigen (HBsAg) to form its viral envelope. HDV causes acute or chronic hepatitis by inducing direct cytopathic effects and immune-mediated liver injury. Coinfection with HBV and HDV or superinfection of HDV in chronic HBV carriers leads to more severe liver disease, including accelerated progression to cirrhosis and increased risk of hepatocellular carcinoma. The virus targets hepatocytes, causing inflammation and necrosis. HDV infection is epidemiologically linked to areas with high HBV prevalence and is transmitted via parenteral routes similar to HBV. The clinical significance lies in its ability to exacerbate HBV-related liver damage and complicate management.
Inciting Event
Exposure to HDV occurs only in the presence of active HBV infection, either as simultaneous co-infection or superinfection.
Parenteral exposure to infected blood or body fluids is the main route of transmission.
Sexual contact with an HBV/HDV-infected individual can trigger infection
Vertical transmission is rare but possible in endemic areas
Latency Period
Incubation period ranges from 3 to 7 weeks after exposure to HDV in the setting of HBV infection.
Symptoms typically develop within 1 to 3 months after infection.
Superinfection in chronic HBV carriers often leads to rapid onset of symptoms and liver decompensation
Diagnostic Delay
Diagnosis is often delayed due to the requirement of concurrent HBV infection for HDV testing.
Lack of routine screening for HDV in HBV-infected patients leads to underdiagnosis.
Symptoms overlap with other causes of hepatitis, causing misattribution to HBV alone
Limited availability of specific HDV antibody and RNA testing in some regions delays diagnosis
Clinical Presentation
Signs & Symptoms
Fatigue and malaise as common systemic symptoms
Right upper quadrant abdominal pain due to liver inflammation
Jaundice presenting as yellow discoloration of skin and eyes
Dark urine and pale stools from cholestasis
Nausea and anorexia during acute hepatitis flare
History of Present Illness
Patients present with acute hepatitis symptoms including fatigue, jaundice, and right upper quadrant pain in the setting of known or unknown HBV infection.
Superinfection often causes a more severe and rapidly progressive hepatitis compared to HBV alone.
Chronic infection may present with signs of chronic liver disease such as ascites, encephalopathy, or variceal bleeding.
Patients may report recent high-risk exposures such as intravenous drug use or unprotected sex
Past Medical History
Known chronic HBV infection is the most important relevant history.
History of intravenous drug use or high-risk sexual behavior increases suspicion for HDV.
Previous episodes of acute or chronic hepatitis or liver dysfunction are relevant.
History of blood transfusions or hemodialysis may increase risk
Family History
Family history of chronic HBV infection or liver disease may be present in endemic areas.
No direct genetic inheritance of HDV occurs, but familial clustering of HBV increases risk.
Family members may share risk factors such as vertical transmission or shared exposures
Physical Exam Findings
Jaundice with yellowing of the sclera and skin due to hyperbilirubinemia
Hepatomegaly indicating liver inflammation or swelling
Spider angiomas and palmar erythema in chronic liver disease
Ascites in advanced liver dysfunction or cirrhosis
Tenderness over the right upper quadrant reflecting hepatic inflammation
Diagnostic Workup
Diagnostic Criteria
Diagnosis of HDV infection requires detection of anti-HDV antibodies (IgM and IgG) and confirmation by HDV RNA PCR to demonstrate active viral replication. It is essential to establish concurrent or prior HBsAg positivity since HDV depends on HBV infection. Elevated liver enzymes (ALT, AST) with clinical hepatitis in an HBV-infected patient should prompt testing for HDV. Serologic testing for anti-HDV IgM indicates recent or active infection, while anti-HDV IgG suggests past or chronic infection. Definitive diagnosis relies on detecting HDV RNA in serum or liver tissue.
Pathophysiology
Key Mechanisms
HDV is a defective RNA virus that requires the hepatitis B virus (HBV) surface antigen (HBsAg) for viral assembly and infectivity.
Co-infection or superinfection with HBV leads to direct cytopathic liver injury mediated by immune responses against infected hepatocytes.
HDV replication causes enhanced hepatic inflammation and accelerated progression to fibrosis and cirrhosis compared to HBV alone.
The virus induces a strong cytotoxic T lymphocyte response that contributes to hepatocyte damage and liver dysfunction.
HDV infection suppresses HBV replication but worsens overall liver injury through immune-mediated mechanisms.
| Involvement | Details |
|---|---|
| Organs | Liver is the central organ involved in HDV infection, where viral replication and immune-mediated damage cause hepatitis and potential progression to cirrhosis. |
Immune system organs such as lymph nodes and spleen participate in mounting the antiviral immune response. | |
| Tissues | Liver parenchyma is the main tissue affected by HDV, showing inflammation, hepatocyte necrosis, and fibrosis. |
Fibrotic tissue develops in chronic infection, leading to cirrhosis and impaired liver function. | |
| Cells | Hepatocytes are the primary target cells for HDV infection and replication, dependent on HBV surface antigen expression. |
Kupffer cells contribute to liver inflammation and fibrosis by releasing proinflammatory cytokines in response to infected hepatocytes. | |
Cytotoxic T lymphocytes mediate immune-mediated hepatocyte injury during HDV infection. | |
| Chemical Mediators | Interferon-alpha is a key antiviral cytokine used therapeutically to enhance immune clearance of HDV. |
Tumor necrosis factor-alpha (TNF-α) promotes hepatic inflammation and fibrosis in chronic HDV infection. | |
Transforming growth factor-beta (TGF-β) drives liver fibrosis by activating hepatic stellate cells. |
Treatments
Pharmacological Treatments
Pegylated Interferon-alpha
- Mechanism:
Enhances host immune response to suppress HDV replication and requires co-infection with HBV.
- Side effects:
Flu-like symptoms
Depression
Cytopenias
- Clinical role:
First-line
Nucleos(t)ide analogs (e.g., Tenofovir, Entecavir)
- Mechanism:
Suppress HBV replication, indirectly reducing HDV propagation since HDV requires HBV surface antigen.
- Side effects:
Renal toxicity
Bone mineral loss
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Regular monitoring of liver function and fibrosis progression with imaging and serologic markers.
Liver transplantation for patients with end-stage liver disease or fulminant hepatic failure due to HDV.
Avoidance of alcohol and hepatotoxic drugs to reduce liver injury.
Prevention
Pharmacological Prevention
HBV vaccination prevents hepatitis B infection and thus HDV co-infection
No specific antiviral therapy is approved for HDV, but pegylated interferon-alpha may reduce viral replication
Antiviral treatment targeting HBV reduces HDV replication indirectly
Non-pharmacological Prevention
Safe sex practices to reduce HBV/HDV transmission
Avoidance of intravenous drug use and needle sharing
Screening blood products to prevent transfusion-related infection
Education on perinatal transmission prevention in HBV-infected mothers
Outcome & Complications
Complications
Fulminant hepatitis causing acute liver failure
Progression to cirrhosis with portal hypertension
Hepatocellular carcinoma as a long-term malignancy risk
Coagulopathy due to impaired liver synthetic function
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hepatitis D (HDV, Requires HBV Co-Infection) versus Hepatitis B Virus (HBV) Infection Alone
Hepatitis D (HDV, Requires HBV Co-Infection) | Hepatitis B Virus (HBV) Infection Alone |
|---|---|
Positive HBsAg with detectable HDV RNA or anti-HDV antibodies indicating co-infection | Positive HBsAg and anti-HBc IgM without detectable HDV RNA or anti-HDV antibodies |
More severe acute hepatitis and faster progression to cirrhosis due to HDV co-infection | Typically self-limited or chronic hepatitis with slower progression |
Exposure to HBV risk factors plus residence or travel in HDV endemic regions or intravenous drug use | Exposure to HBV risk factors without known HDV endemic area or risk |
Hepatitis D (HDV, Requires HBV Co-Infection) versus Hepatitis C Virus (HCV) Infection
Hepatitis D (HDV, Requires HBV Co-Infection) | Hepatitis C Virus (HCV) Infection |
|---|---|
Positive HBsAg and anti-HDV antibodies or HDV RNA with negative HCV markers | Positive anti-HCV antibodies and detectable HCV RNA with negative HBV and HDV markers |
Rapidly progressive hepatitis with more severe liver damage due to HDV superinfection | Often chronic infection with gradual progression to cirrhosis over years |
History of HBV infection or co-exposure in endemic areas | History of blood transfusions, intravenous drug use, or high-risk sexual behavior without HBV exposure |
Hepatitis D (HDV, Requires HBV Co-Infection) versus Autoimmune Hepatitis
Hepatitis D (HDV, Requires HBV Co-Infection) | Autoimmune Hepatitis |
|---|---|
Positive HBsAg and anti-HDV antibodies without autoimmune markers | Elevated ANA, anti-smooth muscle antibodies, and hypergammaglobulinemia |
Acute or chronic hepatitis with poor response to immunosuppression, requiring antiviral therapy | Chronic fluctuating hepatitis responsive to immunosuppressive therapy |
Liver biopsy showing hepatocyte necrosis with viral inclusion bodies and HDV antigen presence | Liver biopsy showing interface hepatitis with plasma cell infiltration |
Hepatitis D (HDV, Requires HBV Co-Infection) versus Alcoholic Hepatitis
Hepatitis D (HDV, Requires HBV Co-Infection) | Alcoholic Hepatitis |
|---|---|
No significant alcohol use but history of HBV infection and HDV risk factors | History of chronic heavy alcohol use |
Elevated ALT and AST with variable ratio, positive viral serologies for HBV and HDV | Elevated AST > ALT with ratio >2, elevated GGT, and macrocytic anemia |
Progressive liver damage despite abstinence due to viral co-infection | Hepatic inflammation related to alcohol intake with potential improvement after abstinence |
Hepatitis D (HDV, Requires HBV Co-Infection) versus Wilson Disease
Hepatitis D (HDV, Requires HBV Co-Infection) | Wilson Disease |
|---|---|
Can present at any age but often in adults with HBV/HDV co-infection | Typically presents in adolescents or young adults |
Positive HBV and HDV serologies without copper metabolism abnormalities | Low serum ceruloplasmin, elevated 24-hour urinary copper, and Kayser-Fleischer rings |
Primarily hepatic manifestations with viral hepatitis symptoms and no neurologic signs | Chronic liver disease with neurologic symptoms and hemolytic anemia |